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Abstract: Fragile X syndrome (FXS) is the most common cause of inherited intellectual disability,
caused by CGG expansion over 200 repeats (full mutation, FM) at the 5′ untranslated region
(UTR) of the fragile X mental retardation 1 (FMR1) gene and subsequent DNA methylation of
the promoter region, accompanied by additional epigenetic histone modifications that result in a
block of transcription and absence of the fragile X mental retardation protein (FMRP). The lack
of FMRP, involved in multiple aspects of mRNA metabolism in the brain, is thought to be the
direct cause of the FXS phenotype. Restoration of FMR1 transcription and FMRP production
can be obtained in vitro by treating FXS lymphoblastoid cell lines with the demethylating agent
5-azadeoxycytidine, demonstrating that DNA methylation is key to FMR1 inactivation. This concept
is strengthened by the existence of rare male carriers of a FM, who are unable to methylate the FMR1
promoter. These individuals produce limited amounts of FMRP and are of normal intelligence. Their
inability to methylate the FMR1 promoter, whose cause is not yet fully elucidated, rescues them
from manifesting the FXS. These observations demonstrate that a therapeutic approach to FXS based
on the pharmacological reactivation of the FMR1 gene is conceptually tenable and worthy of being
further pursued.
Keywords: Fragile X syndrome; FMR1 gene; epigenetic therapy; DNA methylation; histone
modifications; drug treatments
1. Introduction
Hereditary disorders of the epigenetic machinery are a newly delineated group of multiple
congenital anomalies and intellectual disability (ID) syndromes resulting from mutations in genes
encoding components of the epigenetic machinery (acting in trans) or epigenetic alterations at
specific loci (acting in cis), such as Rett syndrome and Kleefstra syndrome. A paradigmatic
condition belonging to this latter group is the Fragile X syndrome (FXS, OMIM #300624), an X-linked
condition with hemizygous males more severely affected than females, characterized by cognitive
impairment, behavioral abnormalities (i.e., anxiety, attention deficit with hyperactivity disorder, social
shyness), muscular hypotonia and some physical signs (i.e., long face, large ears, prominent jaw,
macroorchidism) [1]. Up to 67% of FXS boys meet either the autism disorder (AD) or autism spectrum
disorder (ASD) criteria [2]. In affected individuals examined post-mortem, a higher density of dendritic
spines was found, suggesting a possible failure of synapse elimination. While variously misshapen
spines are characteristic of a number of ID syndromes, the overabundance of spines seen in FXS
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is unusual [3]. A recently meta-analysis sets the frequency of affected males at 1.4:10,000 and that
of affected females at 0.9:10,000, while the prevalence of female carriers of the FXS premutation in
the normal population is 1:291, according to one study [4]. The name FXS was derived from the
folate-sensitive fragile site FRAXA (fragile site, X chromosome, A site) on the long arm of chromosome
X (Xq27.3-Xq28) in affected males [5], corresponding to the locus of the causative gene of the syndrome,
FMR1, which contains in its 5′ untranslated region (UTR) a polymorphic CGG triplet repeat [6].
FXS is almost exclusively caused by expansion of the CGG triplet over 200 repeats (full mutation,
FM), followed by cytosine methylation of both the CGGs and CpG island located in the upstream
promoter region (methylated full mutation, MFM). This epigenetic change is accompanied by histone
modifications typical of a heterochromatic status, incompatible with transcription, thus preventing
translation of the FMRP protein. The causative FXS mutation is a typical loss-of-function mutation,
caused by both a sequence anomaly (CGG expansion) and epigenetic modifications (DNA methylation
and histone changes), in the presence of an intact coding sequence of the gene. The absence of FMRP,
an RNA-binding protein mainly involved in several aspects of mRNA metabolism particularly in the
brain and in synaptic formation and maturation (for a review see [7]), is the ultimate cause of the
FXS phenotype.
A number of CGG between 55 and 200 defines another class of alleles, the premutated alleles
(PM). The PM alleles are at high risk of expanding into FM alleles through maternal meiosis and confer
a risk to develop fragile X-associated tremor/ataxia syndrome (FXTAS, OMIM #300623) and fragile
X-associated primary ovarian insufficiency (FXPOI, OMIM #300624). Overall, these disorders, known
as FRAXopathies [8] or fragile X-related disorders [9], share the CGG triplet instability of the FMR1
gene but are characterized by opposed epigenetic changes, with decreased transcription in FXS patients
(loss-of-function) and increased transcription in PM carriers, resulting in a toxic gain-of-function of the
excess mRNA [10].
This scenario is complicated by the description of rare individuals with apparent normal
phenotype, carriers of an unmethylated full mutation (UFM) with a CGG triplet over 200 repeats,
which is completely unmethylated and retains an euchromatic configuration, compatible with both
transcription and translation of the gene, even though at higher and lower levels respectively, compared
to normal [11–13]. In a chorionic villus sample (CVS) of a FXS fetus the absence of FMRP was observed
at around 11 weeks of gestation due to hypermethylation of the expanded CGG sequence [14], but the
mechanisms through which a FM becomes methylated in FXS patients and not in UFM individuals
remain unclear. In a recent paper it was shown that FMR1 silencing in human embryonic stem cells
(hESCs)-derived neurons is mediated by its own mRNA which hybridizes to the complementary
CGG repeat on the DNA sequence to form an RNA:DNA duplex. Disrupting the interaction of the
mRNA with the CGG repeat seems to prevent silencing of the promoter, supporting a mechanism
of RNA-directed gene silencing. However, it should be noted that the hESCs employed in this work
were already partially methylated, casting some doubts on the conclusions reached by the authors [15].
In any case, this mechanism does not explain the existence of UFM individuals, who preserve the FMR1
transcription in presence of CGG expansion. It should be noted that FMR1 epigenetic gene silencing
takes place already in FXS-hESCs. Using 12 FXS-hESCs it was observed that FMR1 hypermethylation
occurs during the undifferentiated state and thus earlier than 11 weeks and it is tightly linked to FMR1
transcriptional inactivation [16].
1.1. The FMR1 Gene and Its Protein Product
The FMR1 gene was identified by positional cloning by Verkerk et al. [6]. It contains 17 exons
spanning 38 kb [17] and produces a 4.4 kb mRNA, which results in the generation of 12 different
isoforms of FMRP protein through alternative splicing [18], with a molecular weight of 70–80 kDa.
The FMR1 locus includes (from 5′ to 3′) an upstream methylated region, the promoter region, the
CGG stretch and the coding sequence. The boundary of the methylated region is located approximately
650–800 nucleotides upstream from the CGG sequence. In FXS alleles this boundary is no longer visible,
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given that promoter and CGG stretch are also methylated, while it is preserved in UFM alleles [19,20].
The methylation boundary region contains binding sites for various nuclear proteins, including CTCF
(CCCTC-Binding Factor), a possible transcriptional regulator for this locus. This binding is likely
to prevent methylation spreading towards the FMR1 promoter region. CTCF protein was recently
considered as a possible regulator of FMR1 expression, probably modulating its transcription through
chromatin loop formation [20].
The promoter contains approximately 56 CpG sites (CpG island) and includes three initiator-like
(InR) sequences localized about 130 nucleotides (nt) upstream the CGG sequence. The transcription
starts from one of these three transcription start sites within a region of approximately 50 nt, and the
size of the CGG repeat may act as a downstream enhancer/modulator of transcription. Initiation shifts
to the upstream sites when the size of the CGGs expands [21].
The polymorphic CGG repeat is located in the 5′ UTR of exon 1. Based on the CGG expansion
range, three main classes of alleles are described: normal, with 5–55 CGGs; PM, with 56–200 CGGs
and FM, with over 200 CGGs. These latter alleles are subject to hypermethylation and epigenetic
silencing, with consequent loss of FMRP. This loss-of-function mutation is the cause of the FXS
phenotype. A schematic overview of the FMR1 gene structure with the main classes of alleles and
their transcriptional activity is depicted in Figure 1. These three ranges of expansion correlate with
a different transmission pattern through generations: normal alleles are stable; above 56 repeats the
alleles become progressively unstable and can expand to FM during maternal meiosis. So far, the
smallest allele capable of switching from PM to FM in a single maternal meiosis was found to contain
56 CGGs [22]. No case has yet been described of direct expansion from normal to FM. One or two AGG
triplets may be interspersed every 9–10 CGGs [17]. The presence of these AGGs keeps the CGGs stable
during DNA replication, and their presence lowers the risk for maternal PM to be passed down as
a FM [23]. It has been reported that the presence of two interspersed AGGs leads to a 60% decrease
of such risk, in women carrying 70–80 CGGs [24]. Because the number of triplets expands over the
generations, the number of affected individuals increases accordingly. This phenomenon was called
the Sherman paradox [25].
The protein product of FMR1, FMRP can be primarily classified as an RNA-binding protein
that regulates translation of several target mRNAs, and particularly those associated with neuronal
development. The interaction with target mRNAs is mediated by two K homology (KH) domains
and an arginine-glycine-glycine triplet (RGG) box in the central region and C-terminus of the protein,
respectively. The protein has a nuclear localization signal (NLS) and a nuclear export signal (NES), used
to shuttle from nucleus to cytoplasm and back. The fraction of the protein that stays within the nucleus
is only about 4%, the balance being localized in the cytoplasm [26]. FMRP can form homodimers and
interacts with several cytoplasmic and nuclear proteins involved in mRNA metabolism, including
RNA interference (RNAi) [27,28] and RNA editing [29]. It also has a role in cytoskeleton remodeling,
via its N-terminal and central regions. FMRP interactions and functions may be modulated by its
post-translational modifications, such as phosphorylation at amino acids 483 and 521 [30].
There is evidence that the absence of FMRP results in an increased translation rate of its
target mRNAs [31], which is consistent with the idea that FMRP functions as a repressor of
translation, especially at synapses. An example of this mechanism is given by the excess of protein
synthesis secondary to the lack of FMRP, observed after metabotropic glutamate receptor type 5
(mGluR5) stimulation of Fmr1 knock-out mice synapses and represents the basis for the so-called
“mGluR theory” [32]. The absence of FMRP might also induce an increase in the translation of
proteins involved in internalization of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)
receptors (ionotropic glutamate receptors), which could lead to elongation of the dendritic spine and
fewer glutamate ionotropic receptors on the post-synaptic membrane (Figure 2). Fmr1 knockout mice,
heterozygous for mGlur5 (50% reduction of expression of this receptor) showed a rescue of the synaptic
phenotype [33].
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The polymorphic CGG sequence is placed upstream of exon 1 in the 5′ untranslated region (UTR).
Based on the CGG expansion four different cl ss s of all les are shown, with their transcriptional
activity indicated by the arrow: normal ( e utated (PM) wit a higher transcription (bold
arrow) and slight decrease of translation associated to the fragile X-associated tremor/ataxia syndrome
(FXTAS) end fragile X-associated primary ovarian insufficiency (FXPOI) phenotypes; unmethylated
full mutation (UFM), similar to PM for transcription and translation, without an apparent phenotype;
methylated full mutation (MFM) leading to absence of transcript and fragile X mental retardation
protein (FMRP) and consequently to fragile X syndrome (FXS).
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Figure 2. Schematic repres ntation of the t glutamate receptor (mGluR) theory. In normal
den rites FMRP inhibits translation of pre-exi ti s after mGluR stimulation, with normal
ionotropic glutamatergic receptor ( P ) endocytosis. FXS dendrite appears thinner compared
to normal, because mGluR stimulation by glutamate causes an excess of local protein synthesis with
exaggerated long term depression (LTD) due to a higher AMPAR endocytosis activity. The use of a
mGluR inhibitor leads to a normalization of LTD in absence of FMRP.
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In addition to its role in the brain, FMRP plays important functions in other cell types, such as
tumor cells. Its mRNA is overexpressed in hepatocarcinoma cells [34,35] and FXS patients seem to
have lower risk of developing cancer [36,37]. Recently, it was shown that high levels of FMR1-mRNA
in human breast cancer cells increase the probability for these cells to form lung metastases [38].
Within the nucleus, FMRP acts as a chromatin-binding protein, with a function in the DNA
damage response (DDR), playing an important role in gametogenesis. It has been shown that FMRP
occupies meiotic chromosomes and regulates the dynamics of the DDR machinery during mouse
spermatogenesis [39].
1.2. Epigenetic Regulation of FMR1 Transcription
The silencing of the FMR1 gene seems to require several levels of epigenetic regulation (DNA
methylation, histone modifications, chromatin remodeling and RNAi), although the critical mechanism
involved in the silencing is not fully understood [40]. Silenced FM alleles have a heterochromatic
configuration, transcriptionally non permissive, compared to transcriptionally active wild type (WT)
alleles, which are characterized by an “open” euchromatic configuration, permissive for transcription.
Generally, switching from active transcription to transcriptional silencing is a direct consequence of
CGG repeat expansion over 200 units and its consequent epigenetic modifications. An exception to this
rule is represented by the UFM alleles, in which FMR1 transcription persists despite CGG expansion
over 200 repeats.
In FM alleles, the cytosines of the CpG island and of the expanded CGGs become methylated,
histones 3 and 4 (H3 and H4) are deacetylated, lysine 4 on H3 (H3K4) is demethylated, while lysine 9
on H3 (H3K9) becomes methylated, lysine 27 on H3 is trimethylated (H3K27me3) and lysine 20 on H4
(H4K20) increases its methylation status near the CGG expansion [41–43]. All these epigenetic marks
define a heterochromatin configuration, transcriptionally non permissive.
In contrast to the hypoacetylation of FM alleles, PM alleles have 1.5–2 times the normal levels
of acetylated H3 and H4 [44], thought to be responsible for their increased transcription [45]. These
epigenetic modifications confer a more open chromatin structure to the FMR1 promoter and RNAs
transcribed from premutated CGG expansions tend to form hairpins, which may account for the
stalling of the 40S ribosomal subunits and consequently for the translation deficit of PM alleles [46].
The increased transcription of PM alleles may represent a mechanism to compensate for the lower rate
of FMRP translation [47,48]. The excess of FMR1-mRNA was detected in the inclusions of both neurons
and astrocytes of FXTAS patients [49]. This pathogenic model is typically gain-of-function. Although
the pathogenesis of FXPOI, the second PM-associated phenotype, is still unknown, it seems to be
associated with a similar toxic gain-of-function mechanism. This landscape is further complicated by
the existence of UFM alleles, identified in individuals with apparently normal intelligence, belonging
to FXS families [10–12]. Their FMR1 is transcriptionally active, despite a CGG expansion above
200 repeats. The DNA is unmethylated and the histone marks are similar to those of WT alleles (H3
and H4 acetylated, H3K4 methylated and H3K27 dimethylated), with the exception of H3K9 which
remains partially methylated like in FM alleles. The major epigenetic modifications in normal, FXS
and UFM alleles are reported in Table 1. UFM alleles represent the status of FXS cells before FMs are
silenced at around 11 weeks of gestation [14]. Studies in human ESCs showed that DNA methylation
is the last step before silencing of the FMR1 gene occurs. In FX-ESCs, H3K9 dimethylation of the FMR1
promoter was detected before the occurrence of DNA methylation [50] and in induced Pluripotent Stem
(iPS) cells derived from FXS fibroblasts the reprogramming did not influence the DNA methylation and
the histone modification at the FMR1 locus, which remained in a heterochromatic configuration [51].
In FXS-hESCs FMR1 hypermethylation with its consequent transcriptional inactivation occurs during
the undifferentiated state and it is associated to loss of H3K4me2, gain of H3K9me3 and is unrelated to
CTCF binding [16].
Genes 2016, 7, 49 6 of 16
Table 1. Major epigenetic modifications at the FMR1 locus in transcriptionally active (wild type (WT)
and unmethylated full mutation (UFM)) and inactive fragile X syndrome (FXS) alleles.
WT FXS UFM
DNA methylation − (absent) + (present) − (absent)
H3 and H4 acetylation + − +
H3K4 methylation + − +
H3K9 methylation − + +/−
H3K27 dimethylation + − +
H3K27 trimethylation − + −
To identify structure-specific proteins that could recruit components of the silencing machinery,
we explored the role of two proteins. The first was the DNA binding protein CTCF, which was
recently considered as a possible regulator of FMR1 transcription [20]. CTCF binding is absent in
methylated FM alleles and present in UFM alleles. Notably, pharmacological demethylation with
5-aza-2-deoxycytidine (5-azadC) of FXS cells did not restore CTCF binding to the FMR1 gene. CTCF
depletion with siRNA caused a reduction of both FMR1 and FMR1 antisense RNA 1 (FMR1-AS1)
transcription, which however did not appear to be caused by re-methylation of the FMR1 promoter,
both in normal and UFM cell lines. Based on these findings, we concluded that CTCF may have a
complex role in regulating FMR1 expression, probably through the organization of chromatin loops
between sense/antisense transcriptional regulatory regions. The second protein investigated was the
CGG-binding protein (CGGBP1) [52]. CGGBP1 is a highly conserved protein that binds specifically
to unmethylated CGG tracts. Chromatin immunoprecipitation (ChIP) assays clearly demonstrated
that CGGBP1 binds to unmethylated CGG triplets of the FMR1 gene, but not to methylated CGGs.
However, CGGBP1 silencing with shRNAs did not affect FMR1 transcription and CGG expansion
stability in expanded alleles. Although the strong binding to the CGG tract could suggest a role of
CGGBP1 on FMR1 gene expression, these data demonstrate that CGGBP1 has no direct effect on FMR1
transcription and CGG repeat stability.
Transcription of the FMR1 locus includes several noncoding RNAs (ncRNAs), particularly long
ncRNAs (lncRNAs), which can be transcribed from both strands of the gene, sense and antisense.
These lncRNAs may act as modulators of transcription or of the epigenetic landscape of the locus of
origin. The main ncRNA originated from the FMR1 locus is FMR1-AS1, an antisense transcript absent
in FM alleles and upregulated in PM and UFM alleles [20,53]. It is alternatively spliced, polyadenilated
and exported to the cytoplasm. It appears to be driven by two alternative promoters: one is the FMR1
bidirectional promoter and the second is located in the second intron of the FMR1 gene. In both cases
it includes the CGG·GGC repeat sequence. PM and UFM alleles showed a specific alternative splicing
in intron 2 that used a non-consensus CT-AC splice site. Other ncRNAs were further identified, both
in the sense and in the antisense direction. FMR4 is transcribed in the antisense orientation, is absent
in the FM alleles and slightly overexpressed in PM alleles [54]. Additional ncRNAs were recently
identified: FMR5 and FMR6 [55]. The former is a sense lncRNA transcribed from 1 kb upstream of the
FMR1 transcription start site (in the methylated region upstream of the methylation boundary) and
is expressed in WT, PM and FM alleles. The latter is an antisense transcript that overlaps exons 15,
16 and 17, as well as the 3′ UTR, splicing out the introns through non-canonical consensus sites, and
is silenced in expanded alleles (both PM and FM). Although the exact role of these ncRNAs is not
yet elucidated, they could act as regulators of FMR1 transcription, possibly acting as scaffold for
the proteins necessary for heterochromatin formation or as a guide for the recruitment of silencing
complexes, as described for other loci through RNAi [56]. However, knockdown of Dicer, Argonaute 1
(Ago1) and Argonaute 2 (Ago2), which play a key role in RNAi, did not prevent FMR1 gene silencing
in FXS-hESC derived-neurons, ruling out the involvement of RNAi in silencing FM alleles [15]. At the
same time, FMR1 mRNA has been proven capable of forming RNA:DNA hybrids (R-loops) during
transcription when the CGG tract reaches at least the premutation size [57]. These structures are
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commonly formed at expanded repeat loci by the persistent pairing of the nascent mRNA with the
DNA template strand, leaving the non-template DNA strand unpaired. Furthermore, R-loop formation
may be facilitated by hairpin formation on the non-template (CGG-containing) strand that would
reduce the likelihood of reannealing of the two DNA strands [58]. It has also been proven that even
more stable R-loops are formed when UFM alleles are transcribed, as in FXS-hESC [15] and after
pharmacological FMR1 reactivation in a FXS lymphoblastoid cell line [59]. The different stability of
the R-loop (transient in PM and more prolonged in FM) and the probably different conformation
of the unpaired CGG-containing sense strand (more linearized in PM, probably rich in hairpins in
FM) results in opposite results: the more stable R-loop with longer FM alleles blocks transcription
initiation (and elongation) eventually silencing FM [15,59] while the unpaired non-template strand of
PM would actually recruit transcription activators [59]. Therefore, repeat-induced R-loop formation
would have opposing effects depending on its total length: PM alleles would result in more active local
chromatin with increased FMR1 transcription while longer FM alleles would rather block transcription
and effectively induce local heterochromatin formation [58].
2. Therapeutic Approaches for FXS
Two main mechanisms are involved in FMR1 gene silencing: CGG expansion over 200 repeats
and epigenetic modifications (mainly DNA methylation), in presence of an intact open reading frame
(ORF). These mechanisms lead to the absence of FMRP, whose lack causes the FXS phenotype. Thus,
two different approaches could in principle be employed to treat FXS: (a) to normalize the defective
functions due to the lack of FMRP, acting on the pathways in which it is involved; and (b) to restore
FMR1 expression acting on the epigenetic mechanisms involved in the transcriptional inactivation.
Both approaches were tested in vitro (mainly on Fmr1 knock-out mouse brain slices and FXS patient
cells) and in vivo (in animal models and in clinical trials). All clinical trials so far were based on
evidence obtained on animal models, both mouse and Drosophila. It would be of the utmost importance
to test new therapeutic approaches on a human cellular model. FXS-iPS cells were obtained by different
groups, and neurons derived from FXS-iPS cells represent a potentially useful cellular model to test
new drugs.
2.1. Treatments to Compensate for Lack of FMRP
According to plan (a) above, several clinical trials were conducted, all aimed at correcting the FXS
synaptic defect. Most of them stemmed from the discovery of excessive mGLuR signaling at synapses
lacking FMRP [32]. Interesting results were obtained with AFQ056 (Novartis), a selective inhibitor
of mGluR5, on 30 FXS males aged 18–35 years, showing a significant amelioration of hyperactivity
in a subgroup of drug-treated patients [60]. This subgroup had a complete methylation of the FMR1
promoter, while in the non-responder subgroup DNA methylation was incomplete. The hypothesis
that AFQ056 may affect DNA methylation was not supported by an in vitro study [61]. Unfortunately,
these encouraging preliminary results were not confirmed by subsequent trials with AFQ056. Several
other pharmacological trials were performed to try and compensate for the altered function of specific
neuronal receptors or pathways, consequent to lack of FMRP (reviewed in [62]). Considering the large
number of mRNAs targeted by FMRP and the various dysregulated pathways, most of these clinical
trials with a single drug were inconclusive, probably due to compensation mechanisms within a very
complex scenario (mRNAs, pathways and/or FXS clinical phenotype) [63].
2.2. Epigenetic Treatments
The second approach (plan (b) above) to treat FXS is based on the possibility to revert the
epigenetic marks which maintain the mutated FMR1 gene silent. The hypothesis of reversibility
is supported by the existence of UFM individuals who for some yet unknown reasons are unable
to methylate their fully expanded CGG tract allowing FMR1 transcription. This approach may be
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theoretically considered more effective in curing FXS because it goes directly to the cause of the
transcriptional silencing.
DNA methylation likely represents the main epigenetic mark that switches off the expanded
gene. DNA demethylation can be obtained with 5-azacytidine (5-azaC) or, more efficiently, with
5-azadC, that is incorporated as analog of deoxycytidine during cell replication and irreversibly blocks
DNA methyltransferases [64]. Several studies have been performed to try to restore the activity
of FMR1 gene in vitro by inducing DNA demethylation with 5-azadC in lymphoblastoid cell lines
from FXS patients. In 1998, we first achieved in vitro reactivation of the FMR1 FM by treating FXS
lymphoblastoid cell lines with 5-azadC for 7 consecutive days [65]. The reactivation was concomitant
with partial DNA demethylation and partial restoration of FMRP production providing evidence that
hypermethylation of the FMR1 gene and not amplification of the CGG repeat is the major determinant
in abolishing FMRP production [65]. Subsequent experiments refined the understanding of the
reactivation process by analyzing the methylation status of individual CpG sites in the FMR1 promoter
region before and after 5-azadC treatment through bisulphite sequencing analysis. We demonstrated
that 5-azadC-induced demethylation is partial and transient. After 4 weeks from 5-azadC withdrawal,
the FMR1 promoter resumed its methylated status [66]. To better understand the mechanisms of the
FMR1 gene reactivation, we undertook a systematic study of its epigenetic status, testing the acetylation
and methylation of histones H3 and H4, in three different regions of the gene; promoter, exon 1 and
exon 16 before and after treatment of FXS lymphoblastoid cell lines with 5-azadC for 7 consecutive days.
The treatment induced histone acetylation, as well as methylation of H3K4, while only partly reducing
H3K9 methylation [42]. These epigenetic changes appeared to restore an euchromatic configuration of
the FMR1 promoter effectively transforming a MFM (inactive) into an UFM (active) (Figure 3). In a
more recent study we also demonstrated that the demethylating effect of 5-azadC on genomic DNA is
not random, but rather restricted to the promoter region of FMR1, while the methylation boundary
was not affected by treatment. Furthermore, the reactivating effect of 5-azadC was shown to last longer
than previously thought (10–15 days after the last dose of the drug) [67]. In Figure 4 are reported the
main results of this latter paper. Along the same line, Bar-Nur et al. [68] treated FXS-iPS cells and their
derived neurons with 5-azaC and observed a significant FMR1 reactivation after treatment.
A limitation to the possible clinical use of 5-azadC is represented by its toxicity. While 5-azaC
and 5-azadC are generally well tolerated in the treatment of hematological malignancies [69], the
effects of a long-term treatment are unknown. A second obstacle is the apparent requirement for
cell division in order for 5-azadC to be effective, even though two reports suggest that 5-azadC may
require minimal or no incorporation into DNA to effectively reduce levels of DNA methyltransferase
DNMT1 [70,71]. Nonetheless, there are good reasons for trying to identify mutant FMR1 reactivating
compounds having limited or no toxicity, such as, for instance, histone acetylating drugs. We showed
that histone deacetylase inhibitors (butyrate and phenylbutyrate) alone did not reactivate FMR1 in
FXS lymphoblastoid cell lines, but were synergistic with 5-azadC in reactivating the silent gene [72].
Valproic acid (VPA), which acts as histone deacetylases inhibitor but not as DNA demethylator,
was shown to have a modest effect as transcriptional reactivator of mutant FMR1 in vitro [73]. VPA
is widely used to treat epilepsy and bipolar disorder and is also a potent teratogen, it activates
Wnt-dependent gene expression, similar to lithium, the mainstay of therapy for bipolar disorder [74].
In a preliminary safety clinical trial, 10 FXS subjects were treated with VPA for 6 months, showing
a decrease in the hyperactivity phenotype [75]. Similar findings had been previously obtained in a
clinical trial with L-acetylcarnitine (LAC) [76], a natural compound that can efficiently increase histone
acetylation, but is not sufficient to cause FMR1 reactivation when used alone in vitro [41]. Figure 5
reports the major epigenetic modifications observed after VPA and LAC treatment in vitro.
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quantified by real time PCR and the percentage of demethylated clones was evaluated by bisulphite 
sequencing of  the CpG  island of  the FMR1 promoter  region  (Panel B). The effects of 5‐azadC on 
histone marks (acetylation of H3 and H4, increased methylation of H3K4) are reported in panel C. 
Data derived from Refs. [42,65,66]. 
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after treatments with 5‐azadC of 2 different FXS lymphoblastoid cell lines showed increased FMR1‐
mRNA expression at T3 (8 days after last drug administration), decreasing at T6 (18 days after last 
drug administration) and T7  (22 days after  last drug administration). Western blot with antibody 
against FMRP and GAPDH on FXS cell extracts demonstrated that after treatment the expression of 
FMRP was restored and disappeared after 22 days (T7) from the end of the treatment (Panel A). Panel 
B.  Bisulphite  sequencing  of  the  methylation  boundary  including  the  CpG  island  of  the  FMR1 
promoter region before (top‐left) and after (bottom‐left) treatment with 5‐azadC of WT cells showed 
no substantial modification of the methylation profile, while an almost complete demethylation of the 
promoter region, not affecting the methylation boundary was observed in FXS cells (top right). The 
methylation  boundary  is  indicated  by  the  arrow. Dendrogram  of  the methylation  profile  of  the 
analyzed samples demonstrated a clustering of untreated samples compare to treated ones. The heat 
Figure 4. Long-lasting effect of 5-azadC and methylome analysis after treatment. In A are reported the
transcription and translation results of a recent study [66]. The upper panel reports the scheme
of 5-azadC treatment with the relative time points. Relative quantification of FMR1-mRNA by
RT-PCR after treatments with 5-azadC of 2 different FXS lymphoblastoid cell lines showed increased
FMR1-mRNA expression at T3 (8 days after last drug administration), decreasing at T6 (18 days after
last drug administration) and T7 (22 days after last drug administration). Western blot with antibody
against FMRP and GAPDH on FXS cell extracts demonstrated that after treatment the expression
of FMRP was restored and disappeared after 22 days (T7) from the end of the treatment (Panel A).
Panel B. Bisulphite sequencing of the methylation boundary including the CpG island of the FMR1
promoter region before (top-left) and after (bottom-left) treatment with 5-azadC of WT cells showed
no substantial modification of the methylation profile, while an almost complete demethylation of
the promoter region, not affecting the methylation boundary was observed in FXS cells (top right).
The methylation boundary is indicated by the arrow. Dendrogram of the methylation profile of the
analyzed samples demonstrated a clustering of untreated samples compare to treated ones. The
heat map shows some changes in the methylation profile after treatment, that however do not reach
statistical significance (p > 0.05). Data derived from ref. [67].
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The use of L‐acetylcarnitine (LAC) on FXS induces an increase of H3 and H4 acetylation without DNA 
demethylation and transcriptional reactivation (middle left). Valproic acid (VPA) treatment shows a 
slight transcriptional activity with hyperacetylation of H3 and H4 and methylation of H3K4, while 
H3K9  methylation  remains  unmodified.  MBD,  methyl‐binding  domain  protein;  HD,  histone 
deacethylases; Ac, histone acetyl groups. 
3. Conclusions 
Among  rare genetic disorders, FXS appears  to be more amenable  than others  to an effective 
pharmacological  treatment.  FXS  is  strictly  monogenic,  practically  all  patients  having  the  same 
mutation;  the mutation does not  affect  the  coding  sequence of  the gene but  rather  its  reversible 
epigenetic status;  the pathogenic mechanism  is  relatively well elucidated;  the phenotype  (ID and 
behavioral problems)  ranges  from mild  to moderate, and  it does not normally  include  structural 
defects of tissues or organs. However, as testified by several clinical trials, the effective correction of 
a genetic defect continues to be a tremendous challenge, still requiring a wider basic knowledge of 
the pathophysiology underlying the disease. 
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Figure 5. Major epigenetic modifications at the FMR1 locus after histone acetylating treatments.
In anormally active WT allele a permissive euchromatic configuration is present (bottom), while in
methylated full mutation (FXS) the heterochromatic configuration does not allow transcription (top).
The use of L-acetylcarnitine (LAC) on FXS induces an increase of H3 and H4 acetylation without
DNA demethylation and transcriptional reactivation (middle left). Valproic acid (VPA) treatment
shows a slight transcriptional activity with hyperacetylation of H3 and H4 and methylation of H3K4,
while H3K9 methylation remains unmodified. MBD, methyl-binding domain protein; HD, histone
deacethylases; Ac, histone acetyl gr ups.
Besides drugs to treat FXS, further perspectives may be taken into account, based on the newly
available CRISPR/Cas9 gene editing technique. Recently a targeted deletion of trinucleotide repeats
restoring FMR1 gene expression was produced in FXS-ESC and iPS derived-neuronal cells. These
results provide further insights into the molecular mechanisms of FXS and towards future therapies of
trinucleotide repeat disorders [77].
3. Conclusions
Among rare genetic disorders, FXS appears to be more amenable than others to an effective
pharmacological treatment. FXS is strictly monogenic, practically all patients having the same mutation;
the mutation does not affect th coding sequence of th gene but rather its reversible epigenetic status;
the pathogenic mechanism is relatively well elucidated; the phenotype (ID and behavioral problems)
ranges from mild to moderate, and it does not normally include structural defects of tissues or organs.
However, as testified by several clinical trials, the effective correction of a genetic defect continues to
be a tremendous challenge, still requiring a wider basic knowledge of the pathophysiology underlying
t e disease.
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